Novel CDK2/CDK9 inhibitor fadraciclib targets cell survival and DNA damage pathways and synergizes with encorafenib in human colorectal cancer cells with BRAF(V600E)
Open Access
- 6 August 2025
- journal article
- research article
- Published by Springer Nature in Oncogenesis
- Vol. 14 (1) , 1-11
Abstract
The oncogenic BRAF(V600E) mutation activates the ERK1/2 pathway and is detected in 10% of human colorectal cancers (CRCs) where it is associated with poor prognosis. Inhibitors of BRAF have shown only modest efficacy in patients with CRC due to intrinsic drug resistance. We studied the CDK2/CDK9 inhibitor, fadraciclib, alone and in combination with the BRAF inhibitor encorafenib in isogenic human RKO CRC cells with two, one, or no BRAFV600E alleles (RKO+/+, A19+/-, T29-/-) and in BRAF wild-type HCT-116 cells, including Bax knockout HCT-116Bax-/- cells. Treatment with fadraciclib was shown to suppress MCL-1 and phospho-MCL-1 (Ser64), induce a Bax-dependent apoptosis, and inhibit colony formation in a BRAF gene dose-dependent manner. Fadraciclib decreased phosphorylation of RNA polymerase II, indicating suppression of RNA transcription. The tumor growth inhibitory effect of fadraciclib plus encorafenib was synergistic. Fadraciclib decreased Rb phosphorylation, inhibited cell cycle progression, and promoted DNA damage as evidenced by cleavage of PARP, increased pH2AX (ser139), and activation of p53. In RKO+/+ versus A19+/- or T29-/- cells, drug treatment was associated with greater suppression of p-Rb and inhibition of apoptosis and the cell cycle. In a zebrafish xenograft model, fadraciclib plus encorafenib significantly reduced tumor size, concurrent with increased caspase-3 activation. In human CRCs, BRAF mutation was associated with overexpression of CDK2, and CDK9 overexpression was associated with worse patient survival. In conclusion, fadraciclib depletes MCL-1 to potentiate apoptosis and, combined with encorafenib, synergistically suppresses tumor cell growth in a BRAFV600E gene dose-dependent manner. These data suggest a novel therapeutic strategy in CRCs with BRAFV600E.Keywords
Funding Information
- Mayo Clinic (P30 DK084567)
This publication has 78 references indexed in Scilit:
- Cancer takes many paths through G1/STrends in Cell Biology, 2023
- Phase 1 safety, pharmacokinetic and pharmacodynamic study of fadraciclib (CYC065), a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)European Journal of Cancer, 2020
- Developments in zebrafish avatars as radiotherapy sensitivity reporters — towards personalized medicineEBioMedicine, 2020
- Head-to-head comparison of the impact of Aurora A, Aurora B, Repp86, CDK1, CDK2 and Ki67 expression in two of the most relevant gynaecological tumor entitiesArchives of Gynecology and Obstetrics, 2016
- p53-Independent Effects of Mdm22014
- A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic InterventionCancer Cell, 2013
- Histone H2AX Phosphorylation: A Marker for DNA Damage2012
- Phosphorylation of Serine 2 within the RNA Polymerase II C-Terminal Domain Couples Transcription and 3′ End ProcessingMolecular Cell, 2004
- Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cellsInternational Journal of Cancer, 2000
- Cyclin D1 and p53 Overexpression Predicts Multiple Primary Malignant Neoplasms of the Hypopharynx and EsophagusJAMA Otolaryngology–Head & Neck Surgery, 1999